The lonely quest to create a commission to investigate Covid-19
You’re reading the web edition of D.C. Diagnosis, STAT’s weekly newsletter about the politics and policy of health and medicine. Sign up here to receive it in your inbox.
Other health industry players will profit off of Aduhelm
It’s not just Biogen — other diagnostics and pharma companies will profit off of the FDA approval of the new Alzheimer’s drug Aduhelm, too, as doctors rely on complex brain scans to ensure patients are good candidates for the pricey therapy.
Read Original Article: The lonely quest to create a commission to investigate Covid-19 »
